peptidesciences.com retatrutide Vial of unapproved peptide retatrutide

Tirzepatide results timeline Tirzepatide (brand name Mounjaro for diabetes, Zepbound for weight management) is a dual GIP/GLP-1 receptor agonist

JAMA 314(7):687699

For women who have already been on semaglutide and achieved the ceiling of their results, retatrutide offers a biologically distinct mechanism rather than just a higher dose of the same thing

Risk of developing each substance use disorder also declined significantly by 18% for alcohol, 14% for cannabis, 20% for cocaine and nicotine, and 25% for opioids

This product is not a drug, food or cosmetic and may not be misbranded, mislabeled or misused as such

Clues from laboratory models and clinical trials